Johnson & Johnson (JNJ) official guidance
Johnson & Johnson (JNJ) official earnings guidance and management outlook. Each figure management stated is shown with its revisions and the source quote.
See the full Filings Intelligence suiteJNJJOHNSON & JOHNSONFY2026 · ends 2026-12-27
2 metrics1 lowered1 maintainedearnings call · 28d
2026-10-13 13:57:31 UTC17% – 17.5%lowered -1.4%-73 bps – -23 bps vs FY2025
We are also tightening the range of our effective tax rate guidance. Based on our year-to-date results, we now expect a full-year effective tax rate of 17.0%-17.5%.
JNJ · transcript · Q3 FY2026
2026-10-13 13:56:00 UTCOpen source
2026-07-16 04:01:08 UTC17% – 18%-73 bps – 27 bps vs FY2025
Our effective tax rate is now expected to be lower in a range of 17.0%-18.0% for the full year based on year-to-date results.
JNJ · transcript · Q2 FY2026
2026-07-16 04:00:00 UTCOpen source
2026-04-15 04:01:19 UTCmaintaining our guidance
We are maintaining our guidance for net interest expense, net other income, and the effective tax rate for the full year.
JNJ · transcript · Q1 FY2026
2026-04-15 04:00:00 UTCOpen source
2026-01-22 05:01:12 UTC17.5% – 18.5%new
Finally, we are projecting an effective tax rate in the range of 17.5%-18.5%, with the increase largely due to a mixed change with income in higher tax jurisdictions.
JNJ · transcript · Q4 FY2025
2026-01-22 05:00:00 UTCOpen source
2026-10-13 13:57:31 UTC$10.95 – $11.05maintained
Given those updates, we now expect adjusted operational earnings per share in the range of $10.95-$11.05 or 2% at the midpoint.
JNJ · transcript · Q3 FY2026
2026-10-13 13:56:00 UTCOpen source
2026-10-13 12:13:32 UTC$10.95 – $11.05lowered -5.0%
| Adjusted Operational EPS (Diluted)2,4 / Mid-point Change vs. Prior Year / Mid-point | $10.95 – $11.05 / $11.00 1.5% – 2.4% / 2.0% | $10.86 – $11.01 / $10.94 0.7% – 2.1% / 1.4% |
JNJ · EX-99.1 · Q3 FY2026
2026-10-13 12:12:35 UTCOpen source
2026-07-16 04:01:08 UTC$11.5 – $11.65maintained
We are pleased to increase our adjusted operational earnings per share range to $11.50-$11.65, which equates to an increase of $0.18 at the midpoint. This represents a year-on-year adjusted operational EPS growth of 7.3%.
JNJ · transcript · Q2 FY2026
2026-07-16 04:00:00 UTCOpen source
2026-07-15 11:49:51 UTC$11.5 – $11.65raised +1.5%
| Adjusted Operational EPS (Diluted)2,4 / Mid-point Change vs. Prior Year / Mid-point | $11.50 – $11.65 / $11.58 6.6% – 8.0% / 7.3% | $11.30 – $11.50 / $11.40 4.7% – 6.7% / 5.7% |
JNJ · EX-99.1 · Q2 FY2026
2026-07-15 11:49:04 UTCOpen source
2026-04-15 04:01:19 UTC$11.3 – $11.5maintained
Turning to adjusted operational earnings per share, we are increasing our guidance by $0.02 to a range of $11.30-$11.50, representing 5.7% growth at the midpoint.
JNJ · transcript · Q1 FY2026
2026-04-15 04:00:00 UTCOpen source
2026-04-14 11:36:08 UTC$11.3 – $11.5maintained
| Adjusted Operational EPS (Diluted)2,4 / Mid-point Change vs. Prior Year / Mid-point | $11.30 – $11.50 / $11.40 4.7% – 6.7% / 5.7% | $11.28 – $11.48 / $11.38 4.5% – 6.5% / 5.5% |
JNJ · EX-99.1 · Q1 FY2026
2026-04-14 11:35:25 UTCOpen source
2026-01-22 05:01:12 UTC$11.28 – $11.48maintained
Turning to adjusted operational earnings per share, we expect growth of 5.5% at the midpoint for a range of $11.28-$11.48.
JNJ · transcript · Q4 FY2025
2026-01-22 05:00:00 UTCOpen source
2026-01-21 12:47:01 UTC$11.28 – $11.48new
| Adjusted Operational EPS (Diluted)2,4 / Mid-point Change vs. Prior Year / Mid-point | $11.28 – $11.48 / $11.38 4.5% – 6.5% / 5.5% |
JNJ · EX-99.1 · Q4 FY2025
2026-01-21 12:46:18 UTCOpen source
JNJJOHNSON & JOHNSONFY2027 · ends 2027-12-26
1 metric1 newearnings call · 28d
2026-10-13 13:57:31 UTC$1.36new
As a reminder, for your 2027 modeling, we expect Firefly Bio and Sail Biomedicines to have a combined dilutive impact of $1.36 per share on a full-year adjusted earnings per share next year.
JNJ · transcript · Q3 FY2026
2026-10-13 13:56:00 UTCOpen source
JNJJOHNSON & JOHNSONFY2026 · ends 2026-12-27
4 metrics2 lowered1 new1 maintainedearnings call · 28d
2026-10-13 13:57:31 UTC$21Bmaintained6.6% vs FY2025
We remain confident in our full-year free cash flow guidance of approximately $21 billion.
JNJ · transcript · Q3 FY2026
2026-10-13 13:56:00 UTCOpen source
2026-07-16 04:01:08 UTC$21Bmaintained6.6% vs FY2025
As expected, we had significant improvement in the second quarter with year to date totaling approximately $8.7 billion and are on track for our full year free cash flow outlook approaching $21 billion.
JNJ · transcript · Q2 FY2026
2026-07-16 04:00:00 UTCOpen source
2026-04-15 04:01:19 UTC$21Bmaintained6.6% vs FY2025
However, these were expected, and we remain confident in our full-year free cash flow outlook of approximately $21 billion.
JNJ · transcript · Q1 FY2026
2026-04-15 04:00:00 UTCOpen source
2026-01-22 05:01:12 UTC$21Bnew
As we move forward in 2026, we expect to elevate free cash flow generation to approximately $21 billion.
JNJ · transcript · Q4 FY2025
2026-01-22 05:00:00 UTCOpen source
2026-10-13 13:57:31 UTC$150M – $200Mlowered -36.4%
For net interest expense, we are lowering our guidance to $150 million to $200 million.
JNJ · transcript · Q3 FY2026
2026-10-13 13:56:00 UTCOpen source
2026-07-16 04:01:08 UTC$250M – $300M
For net interest expense, we now project $250 million-$300 million, slightly lower than previous guidance.
JNJ · transcript · Q2 FY2026
2026-07-16 04:00:00 UTCOpen source
2026-04-15 04:01:19 UTCmaintaining our guidance
We are maintaining our guidance for net interest expense, net other income, and the effective tax rate for the full year.
JNJ · transcript · Q1 FY2026
2026-04-15 04:00:00 UTCOpen source
2026-01-22 05:01:12 UTC$300M – $400Mnew
We expect net interest expense between $300 million and $400 million.
JNJ · transcript · Q4 FY2025
2026-01-22 05:00:00 UTCOpen source
2026-10-13 13:57:31 UTC-60 bpslowered -180.0%
Regarding operating margin, we now expect a decline of approximately 60 basis points.
JNJ · transcript · Q3 FY2026
2026-10-13 13:56:00 UTCOpen source
2026-07-16 04:01:08 UTC75 bps
At the beginning of the year, we guided to more than a 50 basis point improvement in adjusted pre-tax operating margin. We now expect approximately a 75 basis point improvement, supported by continuing operating efficiencies and anticipated reduction and recoupment of certain tariff-related costs based on the latest rulings.
JNJ · transcript · Q2 FY2026
2026-07-16 04:00:00 UTCOpen source
2026-04-15 04:01:19 UTCat least 50 bps50 bps vs FY2025
We are maintaining our guidance for adjusted pre-tax operating margin to improve by at least 50 basis points in 2026.
JNJ · transcript · Q1 FY2026
2026-04-15 04:00:00 UTCOpen source
2026-01-22 05:01:12 UTCat least 50 bpsnew50 bps vs FY2025
Despite that increased investment, we are planning for our 2026 adjusted pre-tax operating margin to improve by at least 50 basis points.
JNJ · transcript · Q4 FY2025
2026-01-22 05:00:00 UTCOpen source
2026-10-13 13:57:31 UTC$11.05 – $11.15new
We expect reported adjusted earnings per share of $11.05-$11.15 with a midpoint of $11.10 or growth of 2.9%.
JNJ · transcript · Q3 FY2026
2026-10-13 13:56:00 UTCOpen source
JNJJOHNSON & JOHNSONFY2030+ · ends 2030-12-22
1 metric1 newearnings call · 28d
2026-10-13 13:57:31 UTCat least $50Bnew
Our ambition is to become the number one oncology company by 2030, with sales projected to exceed $50 billion.
JNJ · transcript · Q3 FY2026
2026-10-13 13:56:00 UTCOpen source
JNJJOHNSON & JOHNSONFY2026 · ends 2026-12-27
6 metrics2 raised1 lowered2 newearnings call · 28d
2026-10-13 13:57:31 UTC$100.7Blowered -0.5%6.9% vs FY2025
We now expect full-year operational sales growth in the range of 6.7%-7.1%, which represents operational sales of $100.7 billion at the midpoint, or growth of 6.9%.
JNJ · transcript · Q3 FY2026
2026-10-13 13:56:00 UTCOpen source
2026-10-13 12:13:32 UTC$101B – $101.4Braised +0.6%7.2% – 7.7% vs FY2025
| Estimated Reported Sales3/ Mid-point Change vs. Prior Year / Mid-point | $101.0B – $101.4B / $101.2B 7.2% – 7.6% / 7.4% | $100.8B – $101.4B / $101.1B 7.0% – 7.6% / 7.3% |
JNJ · EX-99.1 · Q3 FY2026
2026-10-13 12:12:35 UTCOpen source
2026-07-16 04:01:08 UTC$100.6Blowered -0.5%6.8% vs FY2025
Driven by second quarter performance and uptake of new product launches, we are increasing operational sales growth by $400 million, now expecting operational sales growth for the full year to be in the range of 6.5%-7.1%, with a midpoint of $100.6 billion.
JNJ · transcript · Q2 FY2026
2026-07-16 04:00:00 UTCOpen source
2026-07-15 11:49:51 UTC$100.8B – $101.4Braised +0.3%7% – 7.7% vs FY2025
| Estimated Reported Sales3/ Mid-point Change vs. Prior Year / Mid-point | $100.8B – $101.4B / $101.1B 7.0% – 7.6% / 7.3% | $100.3B – $101.3B / $100.8B 6.5% – 7.5% / 7.0% |
JNJ · EX-99.1 · Q2 FY2026
2026-07-15 11:49:04 UTCOpen source
2026-04-15 04:01:19 UTC$100.8Bmaintained7% vs FY2025
As a result, we estimate reported sales growth between 6.5%-7.5% with a midpoint of $100.8 billion or 7%.
JNJ · transcript · Q1 FY2026
2026-04-15 04:00:00 UTCOpen source
2026-04-14 11:36:08 UTC$100.3B – $101.3Braised +0.8%6.5% – 7.5% vs FY2025
| Estimated Reported Sales3/ Mid-point Change vs. Prior Year / Mid-point | $100.3B – $101.3B / $100.8B 6.5% – 7.5% / 7.0% | $100.0B – $101.0B / $100.5B 6.2% – 7.2% / 6.7% |
JNJ · EX-99.1 · Q1 FY2026
2026-04-14 11:35:25 UTCOpen source
2026-01-22 05:01:12 UTC$100Blowered -0.5%
Turning now to guidance for the full year 2026, we anticipate operational sales growth in the range of 5.7%-6.7%, with a midpoint of $100 billion or 6.2%.
JNJ · transcript · Q4 FY2025
2026-01-22 05:00:00 UTCOpen source
2026-01-21 12:47:01 UTC$100B – $101Bnew
| Estimated Reported Sales3/ Mid-point Change vs. Prior Year / Mid-point | $100.0B – $101.0B / $100.5B 6.2% – 7.2% / 6.7% |
JNJ · EX-99.1 · Q4 FY2025
2026-01-21 12:46:18 UTCOpen source
2026-10-13 12:13:32 UTC$100.5B – $100.9Braised +0.1%
| Operational Sales2 / Mid-point Change vs. Prior Year / Mid-point | $100.5B – $100.9B /$100.7B 6.7% – 7.1% / 6.9% | $100.3B – $100.9B / $100.6B 6.5% – 7.1% / 6.8% |
JNJ · EX-99.1 · Q3 FY2026
2026-10-13 12:12:35 UTCOpen source
2026-07-15 11:49:51 UTC$100.3B – $100.9Braised +0.4%
| Operational Sales2 / Mid-point Change vs. Prior Year / Mid-point | $100.3B – $100.9B / $100.6B 6.5% – 7.1% / 6.8% | $99.7B – $100.7B / $100.2B 5.9% – 6.9% / 6.4% |
JNJ · EX-99.1 · Q2 FY2026
2026-07-15 11:49:04 UTCOpen source
2026-04-15 04:01:19 UTC$100.2Bmaintained
We are increasing our operational sales guidance to be in the range of 5.9%-6.9%, with a midpoint of $100.2 billion or 6.4%.
JNJ · transcript · Q1 FY2026
2026-04-15 04:00:00 UTCOpen source
2026-04-14 11:36:08 UTC$99.7B – $100.7Braised +0.2%
| Operational Sales2 / Mid-point Change vs. Prior Year / Mid-point | $99.7B – $100.7B / $100.2B 5.9% – 6.9% / 6.4% | $99.5B – $100.5B / $100.0B 5.7% – 6.7% / 6.2% |
JNJ · EX-99.1 · Q1 FY2026
2026-04-14 11:35:25 UTCOpen source
2026-01-21 12:47:01 UTC$99.5B – $100.5Bnew
| Operational Sales2 / Mid-point Change vs. Prior Year / Mid-point | $99.5B – $100.5B / $100.0B 5.7% – 6.7% / 6.2% |
JNJ · EX-99.1 · Q4 FY2025
2026-01-21 12:46:18 UTCOpen source
2026-10-13 12:13:32 UTC6.4% – 6.8%raised +1.5%6.4% – 6.8% vs FY2025
| Adjusted Operational Sales1,2 Change vs. Prior Year / Mid-point | 6.4% – 6.8% / 6.6% | 6.2% – 6.8% / 6.5% |
JNJ · EX-99.1 · Q3 FY2026
2026-10-13 12:12:35 UTCOpen source
2026-07-15 11:49:51 UTC6.2% – 6.8%raised +6.6%6.2% – 6.8% vs FY2025
| Adjusted Operational Sales1,2 Change vs. Prior Year / Mid-point | 6.2% – 6.8% / 6.5% | 5.6% – 6.6% / 6.1% |
JNJ · EX-99.1 · Q2 FY2026
2026-07-15 11:49:04 UTCOpen source
2026-04-14 11:36:08 UTC5.6% – 6.6%raised +3.4%5.6% – 6.6% vs FY2025
| Adjusted Operational Sales1,2 Change vs. Prior Year / Mid-point | 5.6% – 6.6% / 6.1% | 5.4% – 6.4% / 5.9% |
JNJ · EX-99.1 · Q1 FY2026
2026-04-14 11:35:25 UTCOpen source
2026-01-22 05:01:12 UTC5.9%maintained5.9% vs FY2025
Acquisitions and divestitures are expected to favorably impact operational growth by approximately 30 basis points, resulting in an adjusted operational sales growth midpoint of 5.9%.
JNJ · transcript · Q4 FY2025
2026-01-22 05:00:00 UTCOpen source
2026-01-21 12:47:01 UTC5.4% – 6.4%new5.4% – 6.4% vs FY2025
| Adjusted Operational Sales1,2 Change vs. Prior Year / Mid-point | 5.4% – 6.4% / 5.9% |
JNJ · EX-99.1 · Q4 FY2025
2026-01-21 12:46:18 UTCOpen source
2026-07-16 04:01:08 UTC$11.6 – $11.75new5.2% – 6.5% vs FY2025
Reported earnings per share is projected to be $11.60-$11.75, or $11.68 at the midpoint, which represents an 8.2% increase over the prior year.
JNJ · transcript · Q2 FY2026
2026-07-16 04:00:00 UTCOpen source
2026-04-15 04:01:19 UTC$11.55new
As such, we now expect reported adjusted earnings per share of $11.55 at the midpoint, or a growth of 7.1%.
JNJ · transcript · Q1 FY2026
2026-04-15 04:00:00 UTCOpen source
2026-04-15 04:01:19 UTCmaintaining our guidance
We are maintaining our guidance for net interest expense, net other income, and the effective tax rate for the full year.
JNJ · transcript · Q1 FY2026
2026-04-15 04:00:00 UTCOpen source
2026-01-22 05:01:12 UTC$1B – $1.2Bnew
We anticipate net other income to be $1 billion-$1.2 billion for 2026, relatively flat to last year.
JNJ · transcript · Q4 FY2025
2026-01-22 05:00:00 UTCOpen source
JNJJOHNSON & JOHNSONFY2029+ · ends 2029-12-23
1 metric1 newearnings call · 2026-04-15 04:01:19 UTC
2026-04-15 04:01:19 UTC$55Bnew
Since announcing our plans to invest $55 billion in U.S.-based manufacturing technology and research and development through early 2029, we are well on our way to reaching that target.
JNJ · transcript · Q1 FY2026
2026-04-15 04:00:00 UTCOpen source
JNJJOHNSON & JOHNSONFY2026 · ends 2026-12-27
1 metric1 newearnings call · 2026-01-22 05:01:12 UTC
2026-01-22 05:01:12 UTC2.4Bnew
Regarding our share count, due to the rapid share price appreciation in the second half of 2025 into early 2026, our diluted share count is increasing to approximately 2.44 billion shares based on U.S. GAAP accounting rules for the diluted share count calculation, in line with how the fourth quarter of 2025 landed.
JNJ · transcript · Q4 FY2025
2026-01-22 05:00:00 UTCOpen source
JNJJOHNSON & JOHNSONFY2025 · ends 2025-12-28
4 metrics1 raised3 newearnings call · 2025-10-15 04:01:29 UTC
2025-10-15 04:01:29 UTC17.5% – 18%new179 bps – 229 bps vs FY2024
We are expecting a higher effective tax rate to be in the range of 17.5%-18% for the full year, with the increase largely due to the recently enacted One Big Beautiful Bill Act.
JNJ · transcript · Q3 FY2025
2025-10-15 04:00:00 UTCOpen source
2025-10-15 04:01:29 UTC$10.8 – $10.9raised +1.6%
As such, our expected adjusted earnings per share guidance remains $10.85 or 8.7% at the midpoint, with a range of $10.80-$10.90.
JNJ · transcript · Q3 FY2025
2025-10-15 04:00:00 UTCOpen source
2025-10-14 11:23:50 UTC$10.63 – $10.73new
| Adjusted Operational EPS (Diluted)2,4 / Mid-point Change vs. Prior Year / Mid-point | $10.63 – $10.73 / $10.68 6.5% – 7.5% / 7.0% | $10.63 – $10.73 / $10.68 6.5% – 7.5% / 7.0% |
JNJ · EX-99.1 · Q3 FY2025
2025-10-14 11:22:58 UTCOpen source
2025-10-15 04:01:29 UTC$0 – $50Mnew
Assuming what we know today as it relates to tariffs for net interest expense, we are now projecting between $0 and $50 million, an improvement from the previous guidance primarily driven by higher cash balances.
JNJ · transcript · Q3 FY2025
2025-10-15 04:00:00 UTCOpen source
2025-10-15 04:01:29 UTC300 bpsnew
We are reiterating our operating margin guide of an approximate 300 basis point improvement for the full year.
JNJ · transcript · Q3 FY2025
2025-10-15 04:00:00 UTCOpen source